Nilotinb Eg (Nilotinib)

Nilotinib targets the BCR‑ABL driven pathway that underlies chronic myeloid leukemia. It is used in the following clinical setting:

• Chronic myeloid leukemia (CML): helps achieve cytogenetic and molecular remission in patients with Philadelphia chromosome‑positive disease.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase by binding to its ATP‑binding site, blocking downstream signaling that drives leukemic cell proliferation and survival. The inhibition also affects related kinases such as c‑KIT and PDGFR, contributing to its antineoplastic activity in chronic myeloid leukemia.

Nilotinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools, often transient.
• Rash: maculopapular skin eruptions.
• Elevated liver enzymes: increased ALT/AST levels.
• Fatigue: generalized tiredness.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Cardiovascular events: myocardial infarction, arterial occlusion.
• QT interval prolongation: risk of serious arrhythmias.
• Severe hepatic injury: marked elevation of liver enzymes or hepatitis.
• Pancreatitis: acute inflammation of the pancreas.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Pulmonary arterial hypertension: elevated pulmonary pressure.

Nilotinib requires careful monitoring and patient education before and during therapy.

• Cardiac assessment: evaluate baseline ECG and monitor QT interval.
• Liver function: check ALT/AST before initiation and periodically.
• Electrolytes: correct hypokalemia, hypomagnesemia, and hypocalcemia to reduce QT risk.
• Drug interactions: avoid concomitant strong CYP3A4 inhibitors or inducers.
• Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with prescriber.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and light.

Nilotinib interacts with several drug classes that can alter its exposure or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise nilotinib plasma levels.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• QT‑prolonging agents (e.g., antiarrhythmics, certain antipsychotics): increase risk of arrhythmia.

Moderate Interactions (Monitor Closely)

• Antacids or proton‑pump inhibitors: may affect absorption; separate dosing by at least 2 hours.
• Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): monitor for muscle toxicity.
• Warfarin: monitor INR as nilotinib can affect anticoagulation control.